Mangoceuticals (MGRX) said late Monday it "strongly refutes" Eli Lilly's (LLY) claims that the company "improperly" imitated its weight-loss Zepbound and Mounjaro medicines.
"MangoRx strongly refutes any and all claims made by Eli Lilly regarding the sale of compounded tirzepatide," the company added.
Eli Lilly filed lawsuits against medical spas and online vendors for selling products claiming to contain tirzepatide, the main ingredient in its weight-loss drug Zepbound.
Eli Lilly did not immediately respond to MT Newswires' request for comment.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments